Market Minds Advisory
Respiratory Measurement Devices Market

Respiratory Measurement Devices Market: Connected Monitors Extend Care Beyond the Clinic

Hospitals and home care providers are converting toward connected, wearable respiratory monitors as chronic pulmonary disease management expands, pushing measurement beyond episodic clinic spirometry into continuous, data-linked tracking of patient lung function.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$3.8BMarket Size 2025
2036 FORECAST VALUE$10.2BBase Case , 2026 to 2036
CAGR 2026 TO 20369.4 %Bull 10.6% / Bear 8.1%
INCREMENTAL OPPORTUNITY$6.0BNet 10- year value creation
EXPANSION MULTIPLE2.46x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Respiratory measurement demand is converting fastest of any pulmonary device category toward connected, wearable monitors, as chronic disease management pushes measurement beyond episodic clinic visits into continuous tracking. Home care programs are accelerating that shift each year. Reimbursement policy increasingly decides which systems win that race today.
Connected and wearable respiratory monitors lead every other segment on growth as providers convert from standalone spirometers toward platforms transmitting lung function data to care teams. India has become the fastest-growing country, driven by rising respiratory disease burden and expanding healthcare access, while North America and East Asia anchor the largest share of demand given their hospital and home monitoring infrastructure. Capnography and gas exchange analyzers remain the second-fastest category as critical care applications expand.
Competitive character remains moderately concentrated among specialty respiratory device manufacturers, evaluated here on installed device and consumable revenue combined. Hospital procurement cycles and clinical validation investment increasingly decide which manufacturer's platform a given health system standardizes on, pushing companies toward accuracy evidence generation well beyond typical device marketing spend. Smaller vendors increasingly struggle to fund the clinical trials that differentiated coverage now requires.
Market Definition
The respiratory measurement devices market covers spirometry systems, pulse oximetry devices, capnography and gas exchange analyzers, peak flow meters and home monitoring devices, plethysmography and pulmonary function testing systems, and connected and wearable respiratory monitors used to measure lung function and respiratory status in clinical and home settings. It excludes mechanical ventilators, oxygen concentrators, and respiratory drug delivery devices not incorporating a measurement function.
Base Year Value
$3.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
9.4% base case. Bull 10.6%. Bear 8.1%.
Fastest Growth Segment
Connected and Wearable Respiratory Monitors: 16.4% CAGR
Fastest Growth Country
India: 14.4% CAGR
Fastest Growth Region
South Asia and Pacific: 11.4% CAGR
Largest Region
North America: 27% of 2025 global value
Market Leaders
Medtronic plc, Koninklijke Philips N.V., Masimo Corporation, ResMed Inc., Vyaire Medical, Inc. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Respiratory Measurement Devices Market Forecast Scenarios

respiratory-measurement-devices-market-size-forecast-scenario-1787306328359
Respiratory measurement demand grew steadily but unevenly between 2020 and 2025. Pandemic-era pulse oximetry demand briefly spiked through 2021, then expanding chronic disease management and growing home monitoring adoption sustained that momentum, lifting historical growth to an estimated 8.4% compound rate. That momentum built gradually as reimbursement pathways matured. Practice reopening timelines varied significantly by country and payer network.
The base case assumes 9.4% annual growth through 2036, anchored on three mechanisms. First, expanding chronic obstructive pulmonary disease and asthma management programs keep pulling health systems toward validated continuous monitoring platforms across both developed and emerging markets. Second, connected device adoption keeps converting users away from standalone spirometers toward platforms commanding meaningfully higher per-device pricing. Third, expanding home monitoring reimbursement keeps broadening the addressable patient population independent of underlying respiratory disease incidence trends.
A bull case builds if connected device reimbursement expands faster than currently expected, pushing growth toward 10.6% as more health systems standardize around continuous monitoring platforms. The bear risk is reimbursement policy delay: if home monitoring coverage expansion extends longer than anticipated, connected device adoption could slow well below expectations, capping growth near 8.1% across the forecast period.

From Episodic Spirometry to Continuous Lung Function Tracking

Respiratory measurement remains fundamentally a broad pulmonary diagnostics category, but the market is undergoing a genuine shift as connected and wearable monitors convert measurement from episodic clinic testing into continuous, longitudinal lung function tracking. Chronic disease management investment is expanding the addressable monitored population well beyond what acute respiratory testing demand alone would predict. That shift increasingly rewards manufacturers who can prove clinical out
MARKET CONCENTRATION51% CR5Five manufacturers hold just over half of category revenue
AVERAGE SELLING PRICE$620 per connected monitorConnected platforms consistently command a meaningful pricing premium
LEADING PRODUCT CATEGORY SHAREPulse oximetry, 36%One legacy product category still dominates total unit volume
HOME MONITORING PENETRATION24% of eligible chronic patientsHome respiratory monitoring remains a minority testing pathway
LEADING PRODUCING COUNTRY SHAREIndia, 12% of global demand growthOne country accounts for a disproportionate share of expansion
SENSOR COMPONENT COST SHARE31% of unit COGSOptical and flow sensor sourcing dominates recurring device cost
Health systems compete less on raw device cost than on demonstrated measurement accuracy and connected reporting capability that continuous monitors make achievable outside the clinic setting. Manufacturing remains concentrated in the United States, Germany, and Japan, while domestic Asian device sectors continue expanding to serve their own growing chronic respiratory disease population. Distribution networks continue consolidating around larger hospital systems.
The next decade will be shaped by two forces pulling in the same direction: expanding chronic pulmonary disease management finally scaling from hospital-based testing into broader home and remote monitoring programs, and connected device capability growing sophisticated enough to expand total device demand regardless of which specific care setting a given patient uses. Both push investment toward connected and capnography platforms even as cost-conscious health systems weigh device cost against still-uneven reimbursement in several markets.
"A spirometry test used to mean an annual appointment and a single number. Now the device tracks lung function every day from the patient's living room."
Director, Respiratory and Pulmonary Diagnostics Practice · MMA Medical Devices P

Market Trends

Connected Monitors Convert Standalone Spirometry Testing

Connected and wearable respiratory monitors, transmitting lung function data directly to care team dashboards and patient records, are converting hospitals and home care providers away from standalone spirometers toward platforms delivering genuine longitudinal disease tracking beyond a single clinic visit. This is pushing pulmonology practices and home care programs to requalify monitoring protocols ahead of typical device replacement cycles, since connected capability eliminates the need for manual result transcription previously required to build a patient's respiratory history. Manufacturers with validated connected platforms are capturing disproportionate share of this conversion wave as additional providers adopt connected technique each year.
Market Impact: Adds 7,200 annual clinic installati

Chronic Disease Management Expands Monitoring Population

Expanding chronic obstructive pulmonary disease and asthma management programs, driven by rising awareness of early intervention benefits, are converting respiratory measurement from a reactive diagnostic step into a routine chronic disease management activity previously reserved for acute exacerbation assessment. This is opening genuinely new monitoring volume among patients whose respiratory decline would previously have gone undetected until later disease stages. Manufacturers with platforms suited to continuous chronic disease tracking are capturing disproportionate share of this expanding monitored population as more management programs reach national coverage. This adoption pathway continues strengthening as more programs reach broader coverage each year.
Market Impact: Compresses measurement uncertainty

Market Opportunities and Growth Drivers

Expanding Home Health Monitoring Sustains Baseline Demand

Home health monitoring investment continues expanding across nearly every major market tracked in this report, driving growing respiratory measurement demand that persists regardless of which specific chronic condition a given household ultimately monitors. This demand base gives the category resilience that pure hospital-based testing trends alone would not provide, since underlying home monitoring investment keeps expanding even as testing priorities shift toward more comprehensive tracking across the field. Manufacturers investing in both standard and next-generation product lines are capturing disproportionate share of this expanding home monitoring base as households increasingly track multiple chronic conditions together.
Market Impact: Adds 33% per-unit cost premium

Improving Sensor Accuracy Compresses Diagnostic Uncertainty

Continued advances in optical and flow sensor accuracy are compressing the measurement uncertainty that has historically limited clinical confidence in home-based respiratory readings, converting what used to be a meaningful trade-off between testing convenience and diagnostic reliability into a narrowing gap that increasingly favors continuous monitoring. This is forcing providers still relying on older sensor generations to requalify testing protocols faster than typical equipment replacement cycles would otherwise allow across affected monitoring programs. Manufacturers with the most accurate sensors are converting this reliability improvement into meaningfully faster adoption across major hospital networks.
Market Impact: Limits coverage across 34% of plans

Market Restraints and Challenges

Connected Platform Cost Slows Broad Access

Connected respiratory monitors carry a meaningful per-unit cost premium over standard standalone spirometers, creating genuine budget friction for cost-sensitive health systems and home care providers evaluating adoption against thin operating margins already under pressure from broader cost increases. The root cause is that connected systems require both specialized wireless transmission hardware and validated data integration software that standard spirometers do not require at comparable manufacturing cost. Manufacturers are mitigating this by developing modular connectivity add-ons and by helping providers offset the premium against reduced downstream hospitalization costs that early detection typically avoids.
Market Impact: Adds 23% connected device adoption

Uneven Home Monitoring Reimbursement Restrains Pace

Reimbursement for home-based respiratory monitoring remains inconsistent across health systems and private payers, creating genuine friction for providers weighing connected device investment against uncertain per-patient revenue recovery relative to traditional clinic-based testing. The underlying cause is that many payer systems still route respiratory monitoring reimbursement through episodic clinic visit codes rather than recognizing continuous remote monitoring directly. Manufacturers are mitigating this by funding outcomes studies and working directly with payers to establish differentiated remote monitoring reimbursement, helping providers justify program investment against demonstrated clinical benefit over time. This evidence-building process typically takes several years to fully shift payer policy.
Market Impact: Adds 2.8 million chronic patients
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the market by diagnostic technology and product type, the classification providers use when specifying measurement capability and comparing manufacturer platforms across competing procurement decisions. This avoids blending upstream sensor chemistry with the downstream care settings that define how these devices are actually purchased. It keeps upstream technology separate from downstream clinical application throughout.
respiratory-measurement-devices-market-market-share-analysis-1787306328893

Connected and Wearable Respiratory Monitors

Connected and wearable respiratory monitors, transmitting continuous lung function and respiratory rate data through wireless connectivity to care team dashboards, remain the fastest-growing category as providers convert from standalone spirometers toward platforms delivering longitudinal chronic disease tracking. Growth concentrates wherever chronic disease management investment intersects with well-funded home care infrastructure, particularly across North America and increasingly India's rapidly expanding respiratory care access. Medtronic and Philips have each expanded connected product certification substantially, recognizing that data integration depth, not device cost alone, decides which manufacturer captures a health system's long-term monitoring relationship. At a 16.4% forecast CAGR, roughly 1.7 times the market average, this segment is pulling capital investment toward connected conversion faster than any other category.
CAGR 16.4%

Capnography and Gas Exchange Analyzers

Capnography and gas exchange analyzers, measuring exhaled carbon dioxide and oxygen consumption to assess ventilation adequacy and metabolic status, track expanding critical care and anesthesia monitoring demand more directly than any other segment, making gas measurement a disproportionate growth driver for this category. Masimo and Vyaire Medical lead on installed clinical platform scale, while newer entrants increasingly compete on response time and integration with anesthesia workstations rather than sensor cost alone. Demand here is tied more closely to critical care capacity expansion than to overall respiratory testing volume, since capnography attach rates rise fastest wherever surgical and intensive care programs mandate continuous ventilation monitoring. This segment's growth trajectory now depends heavily on how quickly hospitals adopt integrated gas monitoring workflows.
CAGR 11.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America and East Asia together anchor the largest share of global demand given their dense concentration of hospital and home monitoring infrastructure, while South Asia and Pacific anchors the fastest-growing regional pipeline. Western Europe contributes steady, more gradually expanding demand of its own. Eastern Europe contributes smaller volume.

North America

The United States anchors regional demand through its dense concentration of hospital systems and the earliest connected monitoring installed base of any market tracked in this report. Canada contributes a smaller, steadily growing demand base benefiting from proximity to the same manufacturer distribution networks and shared clinical training programs serving the broader North American respiratory care community. Deeper reimbursement pathway availability and established home care infrastructure give the region durable spending power even as unit growth moderates relative to faster-growing emerging markets. Growth stays healthy but trails East Asia and South Asia and Pacific because the region's largest health systems have already completed much of their initial platform adoption. Mexico's growing respiratory care capacity adds further regional momentum worth tracking.
Share: 27% | CAGR: 8.8% (2026 to 2036)

Western Europe

Germany anchors both regional instrument manufacturing depth and demand, home to established respiratory device manufacturers and a dense clinical research network whose institutions supply the broader European market. France and the United Kingdom follow with steady demand tied to national health system coverage increasingly recognizing home respiratory monitoring as clinically beneficial. Regulatory harmonization plays a meaningful role here, but European national health service benefit design is pushing providers toward connected adoption well ahead of many other global markets tracked in this report. Growth trails East Asia and South Asia and Pacific because the region's mature diagnostics base is expanding device spending more slowly than newer market entrants. Switzerland and the Netherlands contribute smaller but steadily growing demand of their own.
Share: 23% | CAGR: 7.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
respiratory-measurement-devices-market-country-cagr-analysis-1787306329406

Where Respiratory Device Manufacturers Capture Margin

Standard spirometer sales increasingly compete on price alone as more manufacturers enter the category, so the companies protecting margin monetize the connectivity and evidence layer: data integration software, clinical evidence generation, and long-term hospital network agreements. The four levers below reflect where MMA's interviews with hospital procurement teams show real, sustained willingness to pay a premium.

Data Integration and Remote Reporting Software

Manufacturers increasingly bundle patient record integration and clinician dashboard software alongside connected device sales, since health systems increasingly require documented result tracking and longitudinal reporting capability before approving remote monitoring equipment purchases. Manufacturers investing in comprehensive data integration capture meaningfully higher health system adoption than manufacturers relying on standalone devices alone, worth roughly 25% higher system-level win rates versus standard offerings, since integration investment builds procurement trust that device specification alone cannot replicate. Adoption of dedicated integration teams continues accelerating industry-wide as connected demand expands. This dynamic increasingly shapes vendor selection at contract renewal.
Market Impact: Adds roughly 25 percent higher syst

Clinical Evidence Generation for Payer Coverage

Manufacturers increasingly fund multi-site clinical validation studies demonstrating remote monitoring outcomes benefit, since payers and hospital purchasing committees increasingly require documented clinical evidence before approving reimbursed use of novel monitoring platforms. Manufacturers investing in rigorous clinical evidence capture meaningfully higher payer coverage rates than manufacturers relying on preliminary data alone, worth roughly 24% higher coverage approval versus standard evidence packages, since evidence investment builds purchasing trust that marketing claims cannot replicate on their own. Adoption of dedicated evidence teams continues accelerating industry-wide as coverage expands. Vendors expect this trend to strengthen as evidence standards rise industry-wide.
Market Impact: Adds roughly 24 percent higher paye

Sensor and Consumable Subscription and Loyalty Programs

Manufacturers increasingly convert respiratory monitor sales from one-time device purchases into recurring sensor and consumable subscription programs, since accurate continuous monitoring requires periodic sensor replacement to maintain diagnostic reliability across repeated clinical use. Manufacturers offering subscription-based consumable programs capture meaningfully higher recurring revenue per installed device than manufacturers selling components individually, worth roughly 21% higher lifetime account value, since subscription investment builds procurement predictability that health systems increasingly favor over ad hoc ordering. Adoption of these subscription programs continues expanding as more providers standardize monitoring protocols. Vendors expect this attachment rate to keep climbing as testing volume grows.
Market Impact: Adds roughly 21 percent higher life

Long-Term Hospital Network Supply and Loyalty Agreements

Large hospital networks increasingly sign multi-year device and consumable supply agreements guaranteeing consistent availability and predictable per-unit pricing across their facility networks, converting what used to be a series of individual facility purchase orders into predictable recurring revenue worth roughly 18% of a manufacturer's forward account revenue across the agreement term. Manufacturers offering these agreements gain visibility into future demand that supports continued production investment, while networks gain protection against supply shortages and pricing volatility on devices purchased at high recurring volume each procurement cycle. Smaller manufacturers without similar scale struggle to offer comparable terms.
Market Impact: Locks in supply revenue for 3 to 5

Who Controls the Margin Pool

CR5 sits at 51%, reflecting a category moderately concentrated among specialty respiratory device manufacturers, evaluated here on installed device and consumable revenue combined. Medtronic and Philips lead on category revenue scale, with a moderate gap separating them from smaller challengers, including Masimo and ResMed, each strong in specific application or regional segments rather than universally. Smaller manufacturers increasingly struggle to match the clinical validation investment larg
Current activity centers on three dimensions: data integration and remote reporting software depth, clinical evidence generation for payer coverage, and sensor subscription program capability for large hospital network accounts. Manufacturers lacking connected platform capability are increasingly partnering with specialty software developers rather than losing procurement tenders on missing-technology grounds alone across the industry.

Emerging pressure comes from Chinese domestic diagnostics manufacturers expanding aggressively on price into mid-market hospital segments historically dominated by Western suppliers. If Chinese manufacturers continue converting domestic scale into export competitiveness, expect rankings among the next several challengers to shift by 2030, as lower-cost entrants displace slower-moving incumbents across price-sensitive hospital segments worldwide. Established leaders have limited time to respond before meaningful share shifts occur.
respiratory-measurement-devices-market-company-positioning-matrix-1787306329936

Competitive Moat and Risk Dimensions

MEDTRONIC PLC

Moat: Integrated Respiratory Portfolio Depth

Medtronic's broad, integrated respiratory portfolio spanning ventilation, monitoring, and diagnostic devices gives it switching-cost advantages that narrower single-product manufacturers cannot easily replicate across a hospital's full respiratory procurement relationship. That combined portfolio breadth makes Medtronic a default vendor for health systems seeking a single integrated respiratory relationship. Competitors are unlikely to close this gap quickly.
MEDTRONIC PLC

Risk: Premium Pricing Competitive Exposure

Medtronic's premium device pricing leaves it more exposed than lower-cost competitors to smaller community hospitals and cost-sensitive health systems evaluating procurement against tighter capital budget availability. Managing this requires balancing continued premium positioning against broader market accessibility across the full range of accounts served. This tension is likely to intensify as budget-constrained systems expand purchasing power.
KONINKLIJKE PHILIPS N.V.

Moat: Established Connected Monitoring Evidence

Philips's decades of clinical evidence supporting its connected respiratory monitoring platform give it health system trust and regulatory documentation depth that newer entrants cannot quickly replicate regardless of technical investment committed. That accumulated evidence and relationship depth increasingly functions as a competitive moat for large hospital network procurement decisions specifically.
KONINKLIJKE PHILIPS N.V.

Risk: Capnography Platform Capability Gap

Philips's monitoring-centric portfolio leaves it more exposed than capnography-focused competitors to critical care units seeking integrated gas exchange measurement capability. Closing this gap requires either capital investment in capnography platform development or acquisition of specialized gas analysis developers with established capability. Momentum currently favors capnography-focused rivals in most competitive tenders.

Players Tracked

Prominent Players

Medtronic plc
Koninklijke Philips N.V.
Masimo Corporation
ResMed Inc.
Vyaire Medical, Inc.

Other Key Players

GE HealthCare Technologies Inc.
Nihon Kohden Corporation
Nonin Medical, Inc.
ICU Medical, Inc.
Cosmed S.r.l.
Schiller AG
Baxter International Inc.
Contec Medical Systems Co., Ltd.
Beurer GmbH
Omron Healthcare, Inc.
ndd Medical Technologies, Inc.
Becton, Dickinson and Company
Drägerwerk AG & Co. KGaA
Smiths Group plc
MGC Diagnostics Corporation

Recent Developments

MARCH 2025

Medtronic Expands Connected Monitoring Product Certification

Medtronic announced expanded connected respiratory monitoring product certification, broadening the platform's addressable use across additional chronic disease management applications. The expansion targets health systems seeking validated remote monitoring capability ahead of continued reimbursement expansion this year. The move follows growing provider demand for broader connectivity coverage.
Signal: Signals Medtronic prioritizing connected p
JULY 2025

Philips Launches Expanded Capnography Integration Platform

Philips announced commercial launch of an expanded capnography integration platform engineered for improved workflow connectivity with anesthesia and critical care systems. The launch follows favorable validation data shared with several major hospital network accounts recently. Early customer feedback cited improved workflow confidence across facility networks.
Signal: Signals Philips prioritizing capnography i
NOVEMBER 2025

Masimo Signs Distribution Agreement With Indian Hospital Network

Masimo signed a multi-year distribution agreement with a major Indian hospital network, securing preferred-supplier status for pulse oximetry and connected monitoring platforms ahead of the region's expanding respiratory care investment. The agreement covers device supply and training support across the network's growing facility portfolio this year.
Signal: Signals established manufacturers actively

Optical Sensor and Flow Component Costs

Optical pulse oximetry sensors and precision flow measurement components together account for roughly 31% of respiratory measurement device cost of goods sold, making these inputs the dominant cost driver in the category ahead of general device chassis and packaging labor. Sensor costs vary substantially by accuracy specification, with multi-wavelength discrimination capability driving most of the cost variability manufacturers face today.
Specialty optical sensor component costs spiked through 2022 as broader medical device demand absorbed available specialized manufacturing capacity faster than new capacity could be added, according to company disclosures citing constrained semiconductor sensor availability across multiple regional suppliers. Manufacturers without long-term supply agreements or in-house sensor production capability saw costs rise faster than they could pass through to fixed-price hospital contract pricing signed before the spike occurred across the industry.

Smaller manufacturers without established sensor sourcing relationships absorb input cost volatility directly into thin margins, while larger players like Medtronic and Philips use existing electronics supply chain relationships to insulate margins from component cost swings. Manufacturers newly entering the category without comparable established supply relationships carry meaningfully greater cost exposure than incumbents who capture more of the value chain themselves across the broader category.
respiratory-measurement-devices-market-cost-volatility-analysis-1787306330135

Long-Term Optical Sensor Supply Agreements

The largest manufacturers are locking multi-year optical sensor supply agreements directly with semiconductor production partners rather than competing for spot market capacity, securing priority access and more predictable pricing across major production programs and forecast cycles ahead, reinforcing the scale advantages already present across the category. Smaller manufacturers increasingly struggle to secure comparable terms.

Vertical Integration Into Sensor Manufacturing

Larger manufacturers are investing directly in in-house optical sensor production capability rather than relying entirely on third-party semiconductor suppliers, capturing more of the value chain and reducing exposure to specialty component price swings across the category's highest-volume connected product lines. This trend continues strengthening as demand for validated sensors keeps expanding across every major regional market tracked.

Component Sourcing Diversification Strategies

Manufacturers are diversifying optical and flow sensor component sourcing across multiple regional suppliers rather than depending on a single source, reducing exposure to specific production disruptions that have affected particular semiconductor categories during recent volatility episodes across markets. This diversification has become standard practice among the category's larger manufacturers over the past several procurement cycles industry-wide.

Portfolio Architecture for Margin Defence

MMA's tier architecture separates the category into three margin bands. Volume and commodity-adjacent standard spirometers and pulse oximeters compete on price against widely available generic alternatives and carry thin margin, premium and certified capnography and connected devices carry higher margin on documented accuracy and data integration support, and sustainability-linked next-generation formats, including fully integrated remote monitoring platforms, command the highest margin as the n
The tension between volume and premium plays out most visibly among mid-sized community hospitals, who want connected capability at closer to standard device pricing. That up-tier migration remains slow given how many mid-sized hospitals still evaluate capital budget cost cautiously before committing further procurement resources. Manufacturers that fail to bundle data integration and evidence services risk losing share to more capable rivals.

High-value margin pools concentrate in large hospital network account agreements bundled with data integration, clinical evidence, and consumable subscriptions, where recurring device and service revenue increasingly outweighs the margin earned on any individual device sale alone. That concentration is pulling investment steadily toward connectivity and evidence capability rather than incremental legacy device manufacturing capacity alone across the category.

Volume / Commodity-Adjacent Tier

Standard spirometers and pulse oximeters sold primarily on price against widely available generic alternatives, serving cost-sensitive community hospitals where gross margin stays thin and competition is driven almost entirely by unit cost.
Gross Margin: 17%-22%

Premium / Certified Tier

Capnography and connected devices specified by health systems requiring documented accuracy, data integration, and long-term consumable agreements, commanding meaningfully higher margin on demonstrated performance achieved across major procurement markets today.
Gross Margin: 27%-33%

Sustainability / Regulatory / Next-Generation Tier

Fully integrated remote monitoring platforms positioned for health systems chasing broader chronic disease screening capability and reduced downstream hospitalization costs, where technology innovation and evidence depth support the category's highest margin overall across most major markets today.
Gross Margin: 35%-42%
respiratory-measurement-devices-market-portfolio-architecture-1787306330632

High-value Sub-segments and Strategic Watch-out

Connected and Wearable Respiratory Monitors

The fastest-growing and highest-integration-intensity segment, where health system demand is pulling capital toward validated connected conversion away from standard spirometer formats alone, representing the clearest near-term path to share gain and margin expansion together across a manufacturer's entire network relationship base worldwide. Investment here compounds fastest of any category.
Gross Margin: 31%-38%

Capnography and Gas Exchange Analyzers

Steady, critical-care-driven growth from ventilation monitoring formats that bundle into large hospital network account agreements, less explosive than connected demand but increasingly sticky, giving manufacturers reliable recurring revenue tied to surgical capacity expansion rather than open device competition alone across most accounts. Capital cycles drive most of this growth.
Gross Margin: 26%-32%

Pulse Oximetry Devices

The volume core of the category across established hospitals, sold in steady but modest unit numbers as overall testing volume continues growing, competing on price and least affected by the connectivity-driven dynamics seen elsewhere in the broader portfolio described above, served across most regions today.
Gross Margin: 18%-23%

Peak Flow Meters and Home Monitoring Devices

A strategic watch-out segment where growth trails the category average as adoption remains concentrated among legacy self-monitoring users, and manufacturers risk ceding the niche entirely if larger competitors keep deprioritizing this format ahead of clearer connected demand arriving soon across every affected market and institution type.
Gross Margin: 15%-20%

Hospital Network and Subscription Economics

A device sale is rarely a single transaction for the largest hospital network accounts. Data integration, clinical evidence, and consumable subscriptions convert what used to be a one-time device purchase into a relationship spanning years of recurring reorder and renewal cycles. Manufacturers that capture the subscription and integration attachment at first sale retain more lifetime value per account than those competing on unit price alone.
Adoption depth varies sharply by facility type. Large hospital networks and pulmonology specialty centers convert fastest and most completely, standardizing entire monitoring protocols onto certified, proven suppliers once regulatory and internal purchasing standards align, making them the highest-value account type despite competitive pricing negotiated across the relationship. Independent clinics convert more slowly, often relying on standard spirometers for years before adopting connected or capnography formats directly.

A generational shift in pulmonologists is compounding the connectivity-driven shift. Younger clinicians entering practice increasingly expect connected, data-integrated monitoring tools as standard clinical protocol, a preference an older generation, trained primarily on standalone spirometry alone, rarely weighted as heavily. That shift is accelerating premium-tier adoption even among clinics that have not yet faced direct pressure to convert away from standard devices.
respiratory-measurement-devices-market-end-use-penetration-index-1787306331123

What Matters Most Through 2036

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CONNECTED PLATFORM CAPACITY INVESTMENT

Build validated data integration before competitors do

Connected device demand is converting equipment specification from a differentiated capability into a mainstream health system expectation, and manufacturers with established validated integration platforms are already capturing disproportionate share of purchasing decisions ahead of broader market adoption. Manufacturers that invest in connected capacity now will secure preferred-vendor status with major hospital network accounts before competitors catch up on the integration investment required. Continuing to treat capacity as a future concern risks ceding the fastest-growing, most differentiated segment to manufacturers already building validated integration depth.
02 / SENSOR ACCURACY TECHNOLOGY DEPTH

Deepen measurement precision ahead of the next monitoring cycle

Sensor accuracy technology increasingly decides purchasing decisions as much as unit cost itself, and manufacturers that deepen validated precision pathways will capture disproportionate share of installed hospital relationships as health systems seek diagnostic confidence without full protocol replacement. Manufacturers that invest in open, validated sensor technology now will build switching costs that protect hospital relationships better than competitors relying on price alone. This technology investment requires sustained development spending across multiple years before any single monitoring cycle fully rewards that patient positioning choice.
03 / RECURRING SUBSCRIPTION REVENUE CAPTURE

Bundle integration and subscriptions into every large network quote

Sensor subscription programs and data integration services already generate meaningfully higher recurring revenue than standard device sales, yet many manufacturers still sell these as separate negotiations rather than a default part of every quote presented to large hospital network buyers. Manufacturers that make subscription and integration attachment the default, requiring buyers to actively opt out rather than opt in, will capture more lifetime value per account than competitors treating these services as an afterthought. This remains underexploited by every manufacturer outside the two largest players active in the category.
04 / CHINESE MANUFACTURING COMPETITION

Diversify toward certified segments ahead of continued price pressure

Chinese domestic diagnostics manufacturers continue expanding aggressively into mid-market hospital segments, and manufacturers overly dependent on undifferentiated device sales into price-sensitive markets face real margin compression risk across the forecast period covered in this report. Manufacturers that diversify toward certified, differentiated integration and subscription sales in segments less exposed to Chinese price competition will protect margin better than competitors continuing to compete primarily on undifferentiated commodity-grade device price. This repositioning requires sustained investment in integration well before oversupply pressure fully materializes in each affected market.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Respiratory Measurement Devices Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Respiratory Measurement Devices Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a multi-hospital health system operating 14 facilities, with a growing chronic respiratory disease patient population and a stated goal of standardizing connected monitoring protocols across its network. Annual diagnostics equipment procurement spend exceeds $17 million (client-reported, unverified by MMA), concentrated primarily across spirometers, capnography systems, and emerging connected platforms across its facilities.
STRATEGIC CHALLENGE
The client faced a technology adoption decision balancing connected platform conversion against existing standalone spirometry infrastructure and uncertain reimbursement timing across its varied facility payer mix. Leadership needed a structured evaluation framework weighing data integration benefits against protocol standardization complexity across its facility network and budget. Facility leadership also worried that a rushed rollout could strain clinician workflow across the network.
MMA APPROACH
MMA conducted a structured evaluation of the client's current monitoring practices against connected platform readiness and integration data across its facilities, benchmarked vendor-reported accuracy claims against MMA's proprietary respiratory diagnostics performance database, and facilitated reference site visits with comparable health systems that had already standardized connected protocols. The engagement combined primary interviews with clinical leadership alongside independent performance verification.
KEY FINDINGS
  1. Four of the client's fourteen facilities lacked staff training in connected device data integration required for full program benefit first and foremost.
  2. The client's chronic disease management programs showed meaningfully improved patient follow-up rates with connected devices than with standalone spirometers tested across multiple facility deployments.
  3. Standardizing on validated connected platforms reduced projected manual record-keeping labor by an estimated 24%, per MMA's proprietary internal forecasting model, improving clinician capacity.
  4. Facility-specific payer mix variation across the client's network emerged as a meaningfully underestimated factor in standardization planning requiring further review ahead of the network-wide rollout scheduled for subsequent phases.
CLIENT PROFILE
The client is a multi-hospital health system operating 14 facilities, with a growing chronic respiratory disease patient population and a stated goal of standardizing connected monitoring protocols across its network. Annual diagnostics equipment procurement spend exceeds $17 million (client-reported, unverified by MMA), concentrated primarily across spirometers, capnography systems, and emerging connected platforms across its facilities.
STRATEGIC CHALLENGE
The client faced a technology adoption decision balancing connected platform conversion against existing standalone spirometry infrastructure and uncertain reimbursement timing across its varied facility payer mix. Leadership needed a structured evaluation framework weighing data integration benefits against protocol standardization complexity across its facility network and budget. Facility leadership also worried that a rushed rollout could strain clinician workflow across the network.
MMA APPROACH
MMA conducted a structured evaluation of the client's current monitoring practices against connected platform readiness and integration data across its facilities, benchmarked vendor-reported accuracy claims against MMA's proprietary respiratory diagnostics performance database, and facilitated reference site visits with comparable health systems that had already standardized connected protocols. The engagement combined primary interviews with clinical leadership alongside independent performance verification.
KEY FINDINGS
  1. Four of the client's fourteen facilities lacked staff training in connected device data integration required for full program benefit first and foremost.
  2. The client's chronic disease management programs showed meaningfully improved patient follow-up rates with connected devices than with standalone spirometers tested across multiple facility deployments.
  3. Standardizing on validated connected platforms reduced projected manual record-keeping labor by an estimated 24%, per MMA's proprietary internal forecasting model, improving clinician capacity.
  4. Facility-specific payer mix variation across the client's network emerged as a meaningfully underestimated factor in standardization planning requiring further review ahead of the network-wide rollout scheduled for subsequent phases.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 3): Complete facility-level training and payer assessment and convert the best-positioned facilities to connected monitoring first. Phase 2: Phase 2 (Months 4 to 9): Deploy staff training at remaining facilities while closely tracking follow-up rates against baseline monitoring metrics. Phase 3: Phase 3 (Months 10 to 15): Complete network-wide standardization pending validated results from the initial deployment phase across all facilities.
OUTCOME
The client's first group of converted facilities achieved measurable improvements in patient follow-up rates and record-keeping efficiency within six months of connected standardization (client-reported, unverified by MMA), supporting the phased network-wide rollout that had originally motivated the training assessment engagement. The remaining facilities are scheduled for phased conversion over the following eleven months.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Respiratory Measurement Devices Market?

MMA estimates the global respiratory measurement devices market at $3.8 billion in 2025. Growth concentrates in connected and capnography platforms, driven by expanding chronic disease management.

How large will the Respiratory Measurement Devices Market be by 2036?

MMA forecasts the market reaching $10.21 billion by 2036, up from $4.157 billion in 2026. That represents roughly a 2.46 times expansion over the full ten-year forecast period covered here.

What is the CAGR for the Respiratory Measurement Devices Market 2026 to 2036?

MMA's base case forecasts a 9.4% compound annual growth rate, with a bull case of 10.6% and a bear case of 8.1% depending on connected device reimbursement expansion timing.

Which segment is growing fastest?

Connected and wearable respiratory monitors lead at a 16.4% CAGR, roughly 1.7 times the overall market rate, as providers convert standalone spirometers toward data-linked monitoring platforms.

Who are the major companies in the Respiratory Measurement Devices Market?

Medtronic, Philips, Masimo, ResMed, and Vyaire Medical lead the category, together holding an estimated 51% combined share on a device and consumable revenue basis worldwide.

Which country is growing fastest?

India leads at an estimated 14.4% CAGR, outpacing the global average as rising respiratory disease burden and expanding healthcare access continue growing faster than any comparable economy.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Diagnostic Technology and Product Type

  • Spirometry Systems
  • Pulse Oximetry Devices
  • Capnography and Gas Exchange Analyzers
  • Peak Flow Meters and Home Monitoring Devices
  • Plethysmography and Pulmonary Function Testing Systems
  • Connected and Wearable Respiratory Monitors

By End-Use Care Setting

  • Hospital and Critical Care Use
  • Pulmonology Specialty Clinics
  • Home and Remote Monitoring
  • Occupational and Screening Programs

By Commercial Dimension

  • Direct Hospital Procurement
  • Hospital Network Group Agreements
  • Long-Term Consumable Subscription Contracts
  • Distributor and Reseller Channels

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The respiratory measurement devices market covers spirometry systems, pulse oximetry devices, capnography and gas exchange analyzers, peak flow meters and home monitoring devices, plethysmography and pulmonary function testing systems, and connected and wearable respiratory monitors used to measure lung function and respiratory status in clinical and home settings. It excludes mechanical ventilators, oxygen concentrators, and respiratory drug delivery devices not incorporating a measurement function.
Quantitative Units
USD billions (current prices); installed device count and test volume where applicable
Segmentation Dimensions
By Diagnostic Technology and Product Type; By End-Use Care Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Singapore, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, and additional markets relevant to this sector
Key Companies Profiled
Medtronic plc, Koninklijke Philips N.V., Masimo Corporation, ResMed Inc., Vyaire Medical, Inc., GE HealthCare Technologies Inc., Nihon Kohden Corporation, Nonin Medical, Inc., ICU Medical, Inc., Cosmed S.r.l., Schiller AG, Baxter International Inc., Contec Medical Systems Co., Ltd., Beurer GmbH, Omron Healthcare, Inc., ndd Medical Technologies, Inc., Becton, Dickinson and Company, Drägerwerk AG & Co. KGaA, Smiths Group plc, MGC Diagnostics Corporation
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-107
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Respiratory Measurement Devices Market Report (2026 to 2036).

The full Respiratory Measurement Devices Market report delivers granular five-year and ten-year forecasts across all six technology segments, clinical adoption tracking by region, and manufacturer benchmarking drawn from MMA's proprietary respiratory diagnostics database. It includes detailed profiles of all twenty companies covered here, extended regional analysis across every major hospital and diagnostics market worldwide, and a technology tracker spanning connected and capnography platform development. Subscribers receive quarterly data refreshes through the full forecast period. Buyers also gain direct analyst access for engagement-specific questions throughout the subscription term.
Clinical adoption and coverage tracker by region
Ten-year segment-level forecasts across all technology types
Manufacturer benchmarking data across pricing and validation
Technology platform development tracking module here
Twenty-company competitive profiles with moat analysis
Quarterly data refresh access throughout subscription period

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts